Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017282 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL5114077 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL1037842 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL14620877 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL6426932 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL24912524 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL14772 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL1037843 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL22540086 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A | |
| SCHEMBL12440357 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR5HTR2CHTR6HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | claimed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | claimed |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2009-01-22 | — | — | US | claimed |
| EP-1594520-A2 | USE OF BRADYKININ-B2 RECEPTOR ANTAGONISTS FOR TREATING OSTEOARTHROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-16 | — | — | EP | claimed |
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | claimed |
| WO-2004069266-A2 | USE OF BRADYKININ-B2 RECEPTOR ANTAGONISTS FOR TREATING OSTEOARTHROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-19 | — | — | WO | claimed |
| US-5648333-A | POLYPEPTIDES FOR ANTIINFLAMMATORY AGENTS, WOUND HEALING AGENTS, ANTIALLERGENS OR CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-15 | — | — | US | claimed |
| EP-0370453-B1 | Peptides having a Brady kinine-inhibiting activity | HOECHST AG (DE) | 1994-06-15 | — | — | EP | claimed |
| EP-0370453-A2 | Peptides having a Brady kinine-inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-0370453-A2 | Peptides having a Brady kinine-inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4419517-A | ANALGESICS | E. I. DU PONT DE NEMOURS & CO. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4277608-A | Method of preparing 4a-arylhexahydro-1H-2-pyrindines and 4a-aryloctahydroisoquinolines | ELI LILLY AND COMPANY (US) | 1981-07-07 | — | — | US | disclosed |
| US-4236009-A | Method of preparing 4A-arylhexahydro-1H-2-pyrindines and 4A-aryloctahydroisoquinolines | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4077954-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1575/4885CCR5 2337/4885HTR2C 4499/4885 |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | ALDH1A1 511/4885CCR5 2487/4885HTR2C 2203/4885 |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | ALDH1A1 2482/4885CCR5 4694/4885HTR2C 4435/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | ALDH1A1 2482/4885CCR5 4694/4885HTR2C 4435/4885 |
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | BDKRB2, BDKRB1, PLAT | ALDH1A1 3652/4885CCR5 1367/4885HTR2C 2490/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | ALDH1A1 1273/4885CCR5 2459/4885HTR2C 3033/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1452/4885CCR5 2295/4885HTR2C 4526/4885 |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | BDKRB2, BDKRB1, PLAT | ALDH1A1 3733/4885CCR5 1366/4885HTR2C 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.